All Stories

  1. Survival of dogs with myxomatous mitral valve disease administered preclinical pimobendan in comparison to pimobendan-naïve dogs from the onset of congestive heart failure
  2. Prognostic value of plasma cortisol concentration in dogs with congestive heart failure
  3. Anti‐desmoglein‐2 autoantibodies do not discriminate between UK boxer dogs with and without arrhythmogenic right ventricular cardiomyopathy
  4. Exploring the Role of Transcriptomics, Proteomics, and Machine Learning in HPV Infection and Cardiovascular Disease
  5. Calculation of Myocardial Percentage Collagen, Mast Cell Count and Presence of Arteriosclerosis in Dogs With Myxomatous Mitral Valve Disease and Control Dogs–A Pilot Study
  6. Using a Spectrum of Care Approach to the Diagnosis and Staging of Canine Myxomatous Mitral Valve Disease
  7. Aged Zebrafish as a Spontaneous Model of Cardiac Valvular Disease
  8. Fatal consequences of feline coronavirus infection are associated with virus persistence and a distinct adaptive immune repertoire
  9. Rapid Screening of Anticoagulation Compounds for Biological Target-Associated Adverse Effects Using a Deep-Learning Framework in the Management of Atrial Fibrillation
  10. Sympathetic reactivity to physiological stress is associated with expanded cardiac extracellular volume in humans
  11. Accelerometer-derived classifiers for early detection of degenerative joint disease in cats
  12. Management of preclinical mitral valve disease in dogs
  13. A Deep Learning Methodology for Screening New Natural Therapeutic Candidates for Pharmacological Cardioversion and Anticoagulation in the Treatment and Management of Atrial Fibrillation
  14. Transcriptomics, Proteomics and Bioinformatics in Atrial Fibrillation: A Descriptive Review
  15. Transcriptomics, Proteomics and Bioinformatics in Atrial Fibrillation: A Descriptive Review
  16. Accelerometer-derived classifiers for early detection of degenerative joint disease in cats
  17. Approach to dealing with acute heart failure in cats and dogs
  18. Comparisons of keratinocyte chemoattractant (KC) and monocyte chemoattractant protein-1 (MCP-1) between myxomatous mitral valve disease stages in dogs - a pilot study
  19. Prevalence of gastroesophageal reflux in dogs undergoing MRI for a thoracolumbar vertebral column pathology
  20. Heart rate variability during high‐speed treadmill exercise and recovery in Thoroughbred racehorses presented for poor performance
  21. Improved Ca2+ release synchrony following selective modification of Itof and phase 1 repolarization in normal and failing ventricular myocytes
  22. Validation of a focused echocardiographic training program in first opinion practice
  23. 21st century research—One Health, resilience, welfare, and disease
  24. Training the equine respiratory muscles: Inspiratory muscle strength
  25. The microvascular endothelial glycocalyx: An additional piece of the puzzle in veterinary medicine
  26. Circulating hyaluronan as a marker of endothelial glycocalyx damage in dogs with myxomatous mitral valve disease and dogs in a hypercoagulable state
  27. Training the equine respiratory muscles: Ultrasonographic measurement of muscle size
  28. The prevalence of ultrasonographic gastrointestinal wall changes in dogs with acute pancreatitis - a retrospective study (2012-2020)
  29. Calculation of myocardial percentage collagen and mast cell count in dogs with myxomatous mitral valve disease and control dogs – a pilot study
  30. Three-Dimensional Printed Models of the Heart Represent an Opportunity for Inclusive Learning
  31. Prevalence of ultrasonographic gastrointestinal wall changes in dogs with acute pancreatitis: A retrospective study (2012‐2020)
  32. Effect of preoperative administration of atenolol to dogs with pulmonic stenosis undergoing interventional procedures
  33. Endothelial glycocalyx is damaged in diabetic cardiomyopathy: angiopoietin 1 restores glycocalyx and improves diastolic function in mice
  34. Transvalvular pulmonic stent angioplasty: procedural outcomes and complications in 15 dogs with pulmonic stenosis
  35. Diagnostic Rounds: ECG 101
  36. Computed tomographic staging of dogs with anal sac adenocarcinoma
  37. Clinical findings associated with N‐terminal pro‐B‐type natriuretic peptide measurement in dogs and cats attending first opinion veterinary practices
  38. Inspiratory muscle training for the treatment of dynamic upper airway collapse in racehorses: A preliminary investigation
  39. Evaluation of serum cardiac troponin‐ I concentrations for diagnosis of infective endocarditis in dogs
  40. DETERMINATION OF VERTEBRAL HEART SCALE AND ECHOCARDIOGRAPHIC MEASUREMENTS IN HEALTHY ANESTHETIZED AFRICAN WILD DOGS (LYCAON PICTUS) IN HUMAN CARE
  41. The equine diaphragm: A novel technique for repeatable ultrasound measurement
  42. Focused cardiac ultrasound and point‐of‐care NT‐proBNP assay in the emergency room for differentiation of cardiac and noncardiac causes of respiratory distress in cats
  43. PetSavers
  44. Monitoring congestive heart failure
  45. Long‐term biological variability and the generation of a new reference interval for plasma N‐terminal pro‐B‐type natriuretic peptide in Labrador retrievers
  46. Investigation of focused cardiac ultrasound in the emergency room for differentiation of respiratory and cardiac causes of respiratory distress in dogs
  47. Arrhythmogenic late Ca 2+ sparks in failing heart cells and their control by action potential configuration
  48. Measurements of echocardiographic indices and biomarkers of kidney injury in dogs with chronic kidney disease
  49. What can changes in serial measurements tell us about prognosis in myxomatous mitral valve disease?
  50. Correction: Is treatment with pimobendan associated with an increased risk of arrhythmias in dogs with heart disease?
  51. Exploring early life events including diet in cats presenting for gastrointestinal signs in later life
  52. A new hope? Transvascular pulmonic stents in six dogs with severe pulmonic stenosis
  53. Is treatment with pimobendan associated with an increased risk of arrhythmias in dogs with heart disease?
  54. Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease
  55. Sample Size Determination for Evaluation of Time Domain Heart Rate Variability Indices in Canine Lameness
  56. Pathology and prognosis of canine myxomatous mitral valve disease
  57. Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone—a pilot study
  58. Anodal stimulation in two dogs with transvenous permanent bipolar pacemakers
  59. Differentiation of Cardiac from Noncardiac Pleural Effusions in Cats using Second‐Generation Quantitative and Point‐of‐Care NT ‐pro BNP Measurements
  60. Clinical Severity Score System in Dogs with Degenerative Mitral Valve Disease
  61. The effects of storage conditions on measurements of canine N-terminal pro-B-type natriuretic peptide
  62. Associations between N-terminal procollagen type III, fibrosis and echocardiographic indices in dogs that died due to myxomatous mitral valve disease
  63. Relationship of Plasma N-terminal Pro-brain Natriuretic Peptide Concentrations to Heart Failure Classification and Cause of Respiratory Distress in Dogs Using a 2nd Generation ELISA Assay
  64. Longitudinal Electrocardiographic Evaluation of Dogs with Degenerative Mitral Valve Disease
  65. Differentiating between feline pleural effusions of cardiac and non-cardiac origin using pleural fluid NT-proBNP concentrations
  66. Relationships between heart rate and age, bodyweight and breed in 10,849 dogs
  67. Relationships between heart rate and age, bodyweight and breed in 10,849 dogs
  68. Associations among serum N-terminal procollagen type III concentration, urinary aldosterone-to-creatinine ratio, and ventricular remodeling in dogs with myxomatous mitral valve disease
  69. Selected echocardiographic variables change more rapidly in dogs that die from myxomatous mitral valve disease
  70. Ultrasonographic measurement of flow-mediated vasodilation in dogs with chronic valvular disease
  71. The Combined Prognostic Potential of Serum High-Sensitivity Cardiac Troponin I and N-Terminal pro-B-Type Natriuretic Peptide Concentrations in Dogs with Degenerative Mitral Valve Disease
  72. Gerbode defect associated with blunt trauma in a dog
  73. The effect of protease inhibition on the temporal stability of NT-proBNP in feline plasma at room temperature
  74. Laboratory evaluation of cardiac disease
  75. Investigating the endothelial glycocalyx in health and disease in dogs